The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

Fan, Simin; Shi, Xiaoyan; Yao, Jia; Zhong, Min; Feng, Peimin.
Rev. esp. enferm. dig ; 112(8): 627-635, ago. 2020. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-199968

Documentos relacionados

  1. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
  2. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
  3. The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis.
  4. Structural analysis of the dual agonism at GLP-1R and GCGR.
  5. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.
  6. Evaluation of a pharmacist's impact on the use of glucagon-like peptide-1 receptor agonists for weight management in a family medicine setting.
  7. Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway.
  8. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report.
  9. [Heart and diabetes : What is the importance of GLP-1 receptor agonists in cardiology?]
  10. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.